| 翻訳と辞書 |
| Galecto Biotech ： ウィキペディア英語版 |
Galecto Biotech
Galecto Biotech is a Swedish biotechnology company that has developed a galectin-3 inhibitor that would prevent fibrosis. The galectin-3 inhibitor, TD139, has the potential to treat many diseases due to its involvement in many key biological pathways such as cell differentiation, cell growth, and apoptosis. Galecto Biotech is using this inhibitor to treat idiopathic pulmonary fibrosis (IPF), which is a progressive, irreversible and ultimately fatal lung disease that has poor prognosis and no effective therapies.〔〔 Transforming growth factor is a major mediator of fibrosis and galectin-3 expression is highly upregulated in patients with idiopathic pulmonary fibrosis.〔 TD139 galectin-3 inhibitor, reduces the transforming growth factor (TGF)-β signalling, ultimately showing a strong anti-fibrotic potential that may provide a novel treatment for idiopathic pulmonary fibrosis.〔
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Galecto Biotech」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|